Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX-T in Advanced Pancreatic Cancer
NCT01505413Phase 2Completed
- Sponsor
- Soonchunhyang University Hospital
- Start
- Jan 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in pancreatic cancer (PC), sponsored by Soonchunhyang University Hospital. Primary endpoint: Response Rate at 24 months. Started Jan 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01505413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505413.